Healio Rheumatology peer board previews ACR Convergence 2025
October 25, 2025
4 min learn
ACR Convergence 2025 has come, carrying with it a flood of information to be offered throughout 6 days of conferences, bootcamps, summary classes and lectures, attracting faces each new and acquainted from internationally.
Even for veterans of the assembly — this 12 months scheduled for Oct. 24 to Oct. 29 in Chicago — it may be simple to really feel overwhelmed and even misplaced among the many huge choices.
To assist information attendees of all expertise ranges, Healio Rheumatology requested members of its Peer Perspective Board the next questions:
What are you trying ahead to essentially the most at ACR Convergence 2025? Have any particular classes caught your eye? Is there a subject you might be hoping to see illuminated or elucidated in the course of the assembly? Or are you merely trying ahead to reconnecting with colleagues?
Solutions ranged from suggestions for particular talks — on subjects together with immune-related adversarial results of immune checkpoint remedy, and GLP-1 receptor agonists for osteoarthritis — to an appreciation for the individuals who attend annually.
Here’s what members of the Healio Rheumatology Peer Perspective Board are trying ahead to this 12 months:
Cassandra Calabrese, DO
Assistant professor within the departments of rheumatic and immunologic illness and infectious illness at Cleveland Clinic Lerner Faculty of Drugs of Case Western Reserve College
Cassandra Calabrese
I at all times look ahead to the poster corridor, each for the content material and reconnecting with associates and colleagues.
Additionally, the pre-meeting Fundamental and Medical Analysis Convention on CAR T-cell remedy and immune-related adversarial occasions chaired by Laura C. Cappelli, MD, MHS, and Marcela Maus, MD, PhD, is a must-see session.
Leonard H. Calabrese, DO
Professor of drugs at Cleveland Clinic Lerner Faculty of Drugs of Case Western Reserve College, RJ Fasenmyer chair of scientific immunology on the Cleveland Clinic, and chief medical editor of Healio Rheumatology
Leonard H. Calabrese
I used to be impressed by the variety of abstracts on immune-related adversarial occasions (irAEs) of immune checkpoint inhibitor remedy. Though it seems there have been no main breakthroughs within the discipline of irAEs, the RADIOS Consortium had spectacular output and guarantees to be a extremely productive platform transferring forward.
I used to be additionally very impressed with the almost 30 abstracts on IgG4-related illness. This subject is clearly hitting its stride.
I agree that the Saturday immunotherapy CAR T-cell irAE program seems fabulous.
Laura C. Cappelli, MD, MHS
Co-director of the Immune-Associated Toxicity Group, and affiliate professor of drugs, at Johns Hopkins College
Laura C. Cappelli
I’m trying ahead to the Fundamental and Medical Analysis Convention on immune checkpoints and engineered immune cell remedy, entitled “irAEs and Agonism of Immune Checkpoints to Deal with Autoimmune Illness,” and never simply because I’m co-chairing!
I believe it will likely be a terrific alternative for multidisciplinary dialogue with oncology colleagues about how we should always use CAR T cells and T-cell engagers in autoimmune illnesses. The convention may even give attention to immune checkpoints and their relevance to autoimmune illness, together with immune-related adversarial occasions from immune checkpoint inhibitors used for most cancers remedy.
In sum, the convention will discover an vital a part of the way forward for therapeutics in rheumatology.
Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of drugs, well being care coverage and analysis at Weill Cornell Drugs, and co-director of the Clinic for Inflammatory Arthritis and Biologic Remedy at Hospital for Particular Surgical procedure
Allan Gibofsky
I am trying ahead to reviewing the research offered on CAR T-cell therapies and comparable remedies. I very a lot need to see if the keenness for these novel therapies stays after further information is offered from bigger numbers of sufferers with a number of autoimmune illnesses, hopefully additionally with longer-term remark durations.
I am additionally trying ahead to reconnecting with trainees from my establishment who’ve gone on to determine themselves as scientists and clinicians in different packages.
Nancy E. Lane, MD
Endowed professor of drugs, rheumatology and growing older analysis within the College of California, Davis Well being System
Nancy E. Lane
There’s nothing extra thrilling than seeing the a number of organ programs during which the GLP-1 agonists contact. A session on understanding the position of GLP-1 agonists in knee osteoarthritis won’t be one to overlook. It is going to be thrilling to debate their mechanism of motion. Is it the central nervous system and/or discount in adipose tissue, or each?
One other session that must be thrilling and tweaks my curiosity is entitled, “Skeletal Stem Cells as Therapeutic Targets in Osteoarthritis,” scheduled for Monday, Oct. 27, from 1 to 2 pm. There’s been a lot controversy over which stem cells can truly regenerate muscular skeletal tissues, and I believe this session ought to make clear that.
Philip Web optimization, MD, MHS
Affiliate professor of medicine on the Johns Hopkins College College of Drugs, and rheumatology medical editor for UpToDate
Philip Web optimization
ACR Convergence is like my highschool reunion. It’s a possibility to see a few of my favourite folks from internationally multi functional place.
I’m actually trying ahead to “Flying Solo: Recognizing and Treating Single-Organ Vasculitis,” scheduled for Sunday, Oct. 26, from 3 to 4:30 pm. I believe that is the primary time the ACR has devoted a complete session to single-organ vasculitis, and I’m trying ahead to listening to extra about these illnesses from the specialists.
John R.P. Tesser, MD, FACP, FACR, MACR
Rheumatologist at Arizona Arthritis & Rheumatology Associates, and adjunct assistant professor of drugs at Midwestern College
John R.P. Tesser
I am trying ahead to the response of the rheumatology group to the SetPoint neuro-immunomodulation FDA approval, and the general consequence of this main inflection level within the therapy historical past of rheumatoid arthritis.
For extra info:
Cassandra Calabrese, DO, will be reached at calabrc@ccf.org.
Leonard H. Calabrese, DO, will be reached at calabrl@ccf.org.
Laura C. Cappelli, MD, MHS, will be reached at lcappel1@jhmi.edu.
Allan Gibofsky, MD, JD, MACR, FACP, FCLM, will be reached at gibofskya@hss.edu.
Nancy E. Lane, MD, will be reached at nelane@well being.ucdavis.edu.
Philip Web optimization, MD, MHS, will be reached at web optimization@jhmi.edu.
John R.P. Tesser, MD, FACP, FACR, MACR, will be reached at john.tesser@azarthritis.com.
Sources/Disclosures
Supply:
Healio Interviews
Disclosures:
Cassandra Calabrese, Leonard H. Calabrese, Cappelli, Gibofsky, Lane and Web optimization report no related monetary disclosures. Tesser reviews receiving analysis grants from SetPoint Medical.
